Protective effect of RC-3095, an antagonist of the gastrin-releasing peptide receptor, in experimental arthritis
✍ Scribed by P. G. Oliveira; R. Grespan; L. G. Pinto; L. Meurer; J. C. T. Brenol; R. Roesler; G. Schwartsmann; F. Q. Cunha; R. M. Xavier
- Publisher
- John Wiley and Sons
- Year
- 2011
- Tongue
- English
- Weight
- 302 KB
- Volume
- 63
- Category
- Article
- ISSN
- 0004-3591
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
## Abstract Nude mice bearing xenografts of the androgen‐independent human prostate‐cancer cell line PC‐3 were treated for 4 weeks with somatostatin analog RC‐160, bombesin/gastrin‐releasing peptide (GRP) antagonist (RC‐3095), or the combination of both peptides. In the first experiment, treatment
## Abstract Nude mice bearing xenografts of the gastrin‐responsive human gastric carcinoma MKN45 cell line were treated for 4 to 5 weeks with bombesin/gastrin‐releasing‐peptide(GRP) antagonist (RC‐3095), somatostatin analogues RC‐160 and SMS 201‐995, or the combination of RC‐3095 and RC‐160. Tumor